Eidos Therapeutics, A Bridgebio Company

This study is testing whether a new drug called acoramidis can prevent or delay heart and nerve damage in people who carry a gene for a serious disease but don't yet have symptoms. About 582 adults aged 18-75 with the genetic risk will receive either the drug or a placebo to see …